OTC Markets OTCQB - Delayed Quote USD

NervGen Pharma Corp. (NGENF)

1.9700

+0.0100

+(0.51%)

At close: January 30 at 3:38:28 PM EST

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 8:40 a.m. EST. The conference is being held virtually February 11-12, 2025. Members of management will be ava

Newsfile yesterday

NGENF
+0.51%
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohortThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.Vancouver, British Columbia--(Newsfile Corp. - January 2, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a cli

Newsfile 28 days ago

NGENF
+0.51%
NervGen Announces "At-The-Market" Equity Program

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the "ATM Program") that allows the Company to issue and sell common shares in the capital of the Company (the "Common Shares") to the public from time to time through Stifel Nicolaus Ca

Newsfile last month

NGENF
+0.51%
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completionNVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underwayVancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, reported its financial

Newsfile 2 months ago

NGENF
+0.51%
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20 a.m. EST. Members of management will be available for one-on-one investor meetings during the conference.The conference

Newsfile 2 months ago

NGENF
+0.51%
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) for its proprietary investiga

Newsfile 3 months ago

NGENF
+0.51%
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium, taking place on September 27-28, 2024, in Atlanta, Georgia. Dr. Mikol

Newsfile 4 months ago

NGENF
+0.51%
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting, taking place on September 22-25, 2024, in Antwerp, Belgium.The ISCoS Annual Scientific

Newsfile 4 months ago

NGENF
+0.51%
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at 9:30 a.m. EDT. Members of management will be available for one-on-one investor meetings d

Newsfile 5 months ago

NGENF
+0.51%
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohortNVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI)Vancouver, British Columbia--(Newsfile Corp. - August 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innova

Newsfile 5 months ago

NGENF
+0.51%
Here's Why We're Not At All Concerned With NervGen Pharma's (CVE:NGEN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 5 months ago

NGENF
+0.51%
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual Growth Conference, on August 13, 2024, at 10:00 a.m. EDT and members of management will be available for one-on-one investor meetings at the conference.T

Newsfile 5 months ago

NGENF
+0.51%
NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incentive stock options to existing consultants providing investor relations services exercisable at a price of $2.98 per share. The employee options are e

Newsfile 5 months ago

NGENF
+0.51%
NervGen Pharma Appoints Neil Klompas to Board of Directors

Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGenLeadership appointment supports the company's mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a studyVancouver, British Columbia--(Newsfile Corp. - July 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appoin

Newsfile 6 months ago

NGENF
+0.51%
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug candidate, NVG-300, with a focus on three initial indications: ischemic strok

Newsfile 7 months ago

NGENF
+0.51%
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"), presented by Lineage Cell Therapeutics, Inc., California Institute for Regenerative Medicine and Chri

Newsfile 7 months ago

NGENF
+0.51%
NervGen Pharma Announces Results of Annual General Meeting of Shareholders

All resolutions submitted for approval were passed by shareholdersGlenn Ives appointed as Chair of the BoardJohn Ruffolo appointed as Chair of the Audit CommitteeVancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on June 4, 2024."We ap

Newsfile 7 months ago

NGENF
+0.51%
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific Meeting being held on May 20-23, 2024, in San Juan, Puerto Rico. ASIA gathers resear

Newsfile 8 months ago

NGENF
+0.51%
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024Subacute cohort protocol being amended to enhance feasibility and lessen burden on participantsCA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for

Newsfile 8 months ago

NGENF
+0.51%
NervGen Files Management Information Circular and Announces Board of Directors Transition

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that its Management Information Circular

Newsfile 8 months ago

NGENF
+0.51%

Performance Overview

Return	NGENF	S&P/TSX Composite index
YTD	-8.80%	+4.82%
1-Year	-5.29%	+21.74%
3-Year	+5.91%	+24.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NervGen Pharma Corp. (NGENF)

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

NervGen Announces "At-The-Market" Equity Program

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Here's Why We're Not At All Concerned With NervGen Pharma's (CVE:NGEN) Cash Burn Situation

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

NervGen Pharma Grants Stock Options

NervGen Pharma Appoints Neil Klompas to Board of Directors

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

NervGen Files Management Information Circular and Announces Board of Directors Transition

Performance Overview